BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. J Hepatol. 2017;67:40-46. [PMID: 28213164 DOI: 10.1016/j.jhep.2017.02.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Teo VXY, Heng RRY, Tay PWL, Ng CH, Tan DJH, Ong Y, Tan EY, Huang D, Vathsala A, Muthiah M, Tan EXX. A meta-analysis on the prevalence of chronic kidney disease in liver transplant candidates and its associated risk factors and outcomes. Transpl Int 2021;34:2515-23. [PMID: 34773291 DOI: 10.1111/tri.14158] [Reference Citation Analysis]
2 Kalambokis GN, Christaki M, Tsiakas I, Despotis G, Fillipas-Ntekouan S, Fotopoulos A, Tsiouris S, Xourgia X, Lakkas L, Pappas K, Michalis LK, Sergianiti F, Baltayiannis G, Christodoulou D, Koustousi C, Aggelis N, Milionis H. Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites. J Clin Gastroenterol 2021;55:721-9. [PMID: 32991355 DOI: 10.1097/MCG.0000000000001431] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gillespie S, Hayes PC. Editorial: when to start carvedilol in cirrhosis—time to reconsider? Aliment Pharmacol Ther 2021;54:726-7. [DOI: 10.1111/apt.16512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pfisterer N, Unger LW, Reiberger T. Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. World J Hepatol 2021; 13(7): 731-746 [PMID: 34367495 DOI: 10.4254/wjh.v13.i7.731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
5 Wijarnpreecha K, Li F, Xiang Y, Xu X, Zhu C, Maroufy V, Wang Q, Tao W, Dang Y, Pham HA, Zhou Y, Li J, Zhang X, Xu H, Taner CB, Yang L, Tao C. Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States. Aliment Pharmacol Ther 2021;54:481-92. [PMID: 34224163 DOI: 10.1111/apt.16490] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
6 Garcia-Pagan JC, Francoz C, Montagnese S, Senzolo M, Mookerjee RP. Management of the major complications of cirrhosis: Beyond guidelines. J Hepatol 2021;75 Suppl 1:S135-46. [PMID: 34039484 DOI: 10.1016/j.jhep.2021.01.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Premkumar M, Rangegowda D, Vyas T, Khumuckham JS, Shasthry SM, Thomas SS, Goyal R, Kumar G, Sarin SK. Carvedilol Combined With Ivabradine Improves Left Ventricular Diastolic Dysfunction, Clinical Progression, and Survival in Cirrhosis. J Clin Gastroenterol 2020;54:561-8. [PMID: 31305281 DOI: 10.1097/MCG.0000000000001219] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
8 Wu S, Jiang P, Ding N, Hu Q, Yan X, Liu J, Wang Y, Zhang H, Yuan P, Yang Q. Novel multi-stimuli-responsive supramolecular gel based on quinoline for the fluorescence ultrasensitive detection of Fe3+and Cu2. Spectrochim Acta A Mol Biomol Spectrosc 2021;261:120078. [PMID: 34147737 DOI: 10.1016/j.saa.2021.120078] [Reference Citation Analysis]
9 Li TH, Liu CW, Huang CC, Tsai YL, Huang SF, Yang YY, Tsai CY, Hou MC, Lin HC. Non-Selective Beta-Blockers Decrease Infection, Acute Kidney Injury Episodes, and Ameliorate Sarcopenic Changes in Patients with Cirrhosis: A Propensity-Score Matching Tertiary-Center Cohort Study. J Clin Med 2021;10:2244. [PMID: 34064207 DOI: 10.3390/jcm10112244] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Kang SH, Lee M, Kim MY, Lee JH, Jun BG, Kim TS, Choi DH, Suk KT, Kim YD, Cheon GJ, Kim DJ, Baik SK. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study. Hepatol Int 2021;15:424-36. [PMID: 33860898 DOI: 10.1007/s12072-021-10160-3] [Reference Citation Analysis]
11 Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM, Wilkes EA, Moore K, Leithead JA, Hayes PC, O'Brien AJ, Verma S. Guidelines on the management of ascites in cirrhosis. Gut 2021;70:9-29. [PMID: 33067334 DOI: 10.1136/gutjnl-2020-321790] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 47.0] [Reference Citation Analysis]
12 Pfisterer N, Schmidbauer C, Riedl F, Maieron A, Stadlbauer V, Hennlich B, Schwarzer R, Puespoek A, Bucsics T, Effenberger M, Bota S, Gschwantler M, Peck-Radosavljevic M, Mandorfer M, Madl C, Trauner M, Reiberger T. Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. Wien Klin Wochenschr. 2021;133:421-431. [PMID: 33270161 DOI: 10.1007/s00508-020-01769-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol 2021;27:425-36. [PMID: 33317244 DOI: 10.3350/cmh.2020.0234] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Yang J, Ge K, Chen L, Yang JL. The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: a meta-analysis. Eur J Gastroenterol Hepatol 2019;31:1518-26. [PMID: 31094853 DOI: 10.1097/MEG.0000000000001442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Shalimar, Vaishnav M, Elhence A, Kumar R, Mohta S, Palle C, Kumar P, Ranjan M, Vajpai T, Prasad S, Yegurla J, Dhooria A, Banyal V, Agarwal S, Bansal R, Bhattacharjee S, Aggarwal R, Soni KD, Rudravaram S, Singh AK, Altaf I, Choudekar A, Mahapatra SJ, Gunjan D, Kedia S, Makharia G, Trikha A, Garg P, Saraya A. Outcome of Conservative Therapy in Coronavirus disease-2019 Patients Presenting With Gastrointestinal Bleeding. J Clin Exp Hepatol 2021;11:327-33. [PMID: 33519132 DOI: 10.1016/j.jceh.2020.09.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Sharma S, Agarwal S, Gunjan D, Kaushal K, Anand A, Mohta S, Shalimar, Saraya A. Long-term Outcomes with Carvedilol versus Propranolol in Patients with Index Variceal Bleed: 6-year Follow-up Study. J Clin Exp Hepatol 2021;11:343-53. [PMID: 33994717 DOI: 10.1016/j.jceh.2020.08.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Elhence A, Shalimar. Letter: early TIPSS in acute variceal bleed-debate continues. Aliment Pharmacol Ther 2020;52:579-80. [PMID: 32656838 DOI: 10.1111/apt.15909] [Reference Citation Analysis]
18 Yoon KT, Liu H, Lee SS. Cirrhotic Cardiomyopathy. Curr Gastroenterol Rep 2020;22:45. [PMID: 32651721 DOI: 10.1007/s11894-020-00783-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
19 Haukeland JW, Småstuen MC, Pålsdatter PP, Ismail M, Konopski Z, Jørgensen KK, Lannerstedt H, Midgard H. Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway. PLoS One 2020;15:e0230263. [PMID: 32163489 DOI: 10.1371/journal.pone.0230263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
20 Yoo JJ, Kim SG, Kim YS, Lee B, Jeong SW, Jang JY, Lee SH, Kim HS, Jun BG, Kim YD, Cheon GJ. Propranolol plus endoscopic ligation for variceal bleeding in patients with significant ascites: Propensity score matching analysis. Medicine (Baltimore) 2020;99:e18913. [PMID: 32000397 DOI: 10.1097/MD.0000000000018913] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2020;2:100063. [PMID: 32039404 DOI: 10.1016/j.jhepr.2019.12.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 19.5] [Reference Citation Analysis]
22 Magaz M, Baiges A, Hernández-Gea V. Precision medicine in variceal bleeding: Are we there yet? J Hepatol. 2020;72:774-784. [PMID: 31981725 DOI: 10.1016/j.jhep.2020.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
23 Bultas AC, Teshome B, Richter SK, Schafers S, Cooke E, Call WB. Use of Nonselective β-Blockers in Patients With End-Stage Liver Disease and Select Complications. Ann Pharmacother 2020;54:583-93. [DOI: 10.1177/1060028019893092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Feng LH, Sun HC, Zhu XD, Zhang SZ, Li KS, Li XL, Li Y, Tang ZY. Renin-angiotensin inhibitors were associated with improving outcomes of hepatocellular carcinoma with primary hypertension after hepatectomy. Ann Transl Med 2019;7:739. [PMID: 32042755 DOI: 10.21037/atm.2019.11.131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
25 Lee PC, Chen YJ, Chou YC, Lee KC, Chen PH, Kao WY, Huang YH, Huo TI, Lin HC, Hou MC, Lee FY, Wu JC, Su CW. Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2020;32:365-72. [PMID: 31688303 DOI: 10.1097/MEG.0000000000001511] [Reference Citation Analysis]
26 Hsu WF, Yu SH, Lin JT, Wu JC, Hou MC, Huang YH, Wu CY, Peng CY. Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study. Gastroenterol Res Pract 2019;2019:1743290. [PMID: 31687012 DOI: 10.1155/2019/1743290] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Wong RJ, Robinson A, Ginzberg D, Gomes C, Liu B, Bhuket T. Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: A meta-analysis. Liver Int 2019;39:1080-8. [PMID: 30614656 DOI: 10.1111/liv.14040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
28 Wong F, Reddy KR, O’leary JG, Tandon P, Biggins SW, Garcia‐tsao G, Maliakkal BJ, Lai JC, Fallon MB, Vargas HE, Subramanian R, Thuluvath PJ, Kamath PS, Thacker L, Bajaj JS. Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Transpl 2019;25:870-80. [DOI: 10.1002/lt.25454] [Cited by in Crossref: 17] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
29 Tripathi D, Hayes PC, Richardson P, Rowe I, Ferguson J, Devine P, Mathers J, Poyner C, Jowett S, Handley K, Grant M, Slinn G, Ahmed K, Brocklehurst P. Study protocol for a randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE trial). BMJ Open Gastroenterol. 2019;6:e000290. [PMID: 31139428 DOI: 10.1136/bmjgast-2019-000290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
30 Sharma M, Singh S, Desai V, Shah VH, Kamath PS, Murad MH, Simonetto DA. Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis. Hepatology 2019;69:1657-75. [PMID: 30125369 DOI: 10.1002/hep.30220] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
31 Kockerling D, Nathwani R, Forlano R, Manousou P, Mullish BH, Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25(8): 888-908 [PMID: 30833797 DOI: 10.3748/wjg.v25.i8.888] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
32 Chen WC, Hsin IF, Chen PH, Hsu PI, Wang YP, Cheng JS, Lin HS, Hou MC, Lee FY. Addition of Carvedilol to Gastric Variceal Obturation Does Not Decrease Recurrence of Gastric Variceal Bleeding in Patients With Cirrhosis.Clin Gastroenterol Hepatol. 2019;17:2356-2363. [PMID: 30772583 DOI: 10.1016/j.cgh.2019.02.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
33 Meng D, Li Z, Wang G, Ling L, Wu Y, Zhang C. Carvedilol attenuates liver fibrosis by suppressing autophagy and promoting apoptosis in hepatic stellate cells. Biomedicine & Pharmacotherapy 2018;108:1617-27. [DOI: 10.1016/j.biopha.2018.10.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
34 Durand F, Francoz C, Asrani SK, Khemichian S, Pham TA, Sung RS, Genyk YS, Nadim MK. Acute Kidney Injury After Liver Transplantation. Transplantation 2018;102:1636-49. [DOI: 10.1097/tp.0000000000002305] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
35 Unger LW, Berlakovich GA, Trauner M, Reiberger T. Management of portal hypertension before and after liver transplantation. Liver Transpl. 2018;24:112-121. [PMID: 28752925 DOI: 10.1002/lt.24830] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
36 Facciorusso A, Roy S, Livadas S, Fevrier-paul A, Wekesa C, Kilic ID, Chaurasia AK, Sadeq M, Muscatiello N. Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites. Dig Dis Sci 2018;63:1737-46. [DOI: 10.1007/s10620-018-5092-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
37 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
38 Tholey D, Roth N, Schiano T. PRO ("The Window Is Open"): In patients with cirrhosis with prior variceal hemorrhage and ascites, the clinical benefits of nonselective beta-blockers outweigh the risks and should be prescribed. Clin Liver Dis (Hoboken) 2018;11:119-22. [PMID: 30992801 DOI: 10.1002/cld.700] [Reference Citation Analysis]
39 Mandorfer M, Reiberger T. Role of diuretics in the harmful effects of beta blockers in patients with ascites. Author’s reply. Digestive and Liver Disease 2018;50:102-3. [DOI: 10.1016/j.dld.2017.09.135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Thalheimer U, Giannelli V, Francoz C, Maimone S. Non selective beta blockers in cirrhosis. J Hepatol 2017;67:1342-3. [PMID: 28789879 DOI: 10.1016/j.jhep.2017.05.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
41 Mandorfer M, Reiberger T. Reply to: "Non selective beta blockers in cirrhosis". J Hepatol 2017;67:1343-4. [PMID: 28789883 DOI: 10.1016/j.jhep.2017.07.018] [Reference Citation Analysis]
42 Mallet M, Rudler M, Thabut D. Variceal bleeding in cirrhotic patients. Gastroenterol Rep (Oxf). 2017;5:185-192. [PMID: 28852523 DOI: 10.1093/gastro/gox024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
43 Moctezuma-Velazquez C, Kalainy S, Abraldes JG. Beta-blockers in patients with advanced liver disease: Has the dust settled? Liver Transpl. 2017;23:1058-1069. [PMID: 28590564 DOI: 10.1002/lt.24794] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]